The thyrotrophin-releasing hormone analogue MK771 induces tic-like behaviours: The effects of dopamine D1 and D2 receptor antagonists

European Journal of Pharmacology

Volumn 369, Issue 1, 1999, Pages 1-9

  McCreary, Andrew C ^a   Handley, Sheila L ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Blinking; Dopamine; Forepaw licking; Thyrotrophin releasing hormone (TRH)

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ECOPIPAM; PYRO 2 AMINOADIPYLHISTIDYLTHIAZOLIDINE 4 CARBOXAMIDE; RACLOPRIDE; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLINKING; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; FOREFOOT; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; LICKING; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIC;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BEHAVIORAL SYMPTOMS; BENZAZEPINES; BLINKING; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; RACLOPRIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SULPIRIDE; THIAZOLIDINES; THYROTROPIN-RELEASING HORMONE; TIC DISORDERS;

EID: 0032993521     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00039-4     Document Type: Article

References (71)

1. Adams, R.D., Victor, M., 1981. Principles of Neurology, 2nd edn. McGraw-Hill, New York.
2. Agarwal R.A., Rastogi R.B., Singhal R.L. Enhancement of locomotor activity and catecholamine and 5-hydroxytryptamine metabolism by thyrotrophin releasing hormone. Neuroendocrinology. 23:1977;236-247.
3. Annunziato L., Cerrito F., Raiteri M. Characteristics of dopamine release from isolated nerve endings of the tuberoinfundibular neurones. Neuropharmacology. 20:1984;727-734.
4. 2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur. J. Pharmacol. 133:1987;137-145.
5. Bonnet, K.A., 1982. Neurobiological dissection of Tourette syndrome: a neurochemical focus on a human neuroanatomical model. In: Friedhoff, A.J., Chase, T.N. (Eds.), Gilles de la Tourette Syndrome. Adv. Neurol. 35. Raven Press, New York, pp. 77-82.
6. Boulton C.S., Handley S.L. Factors modifying the head-twitch response to 5-hydroxytryptophan. Psychopharmologia (Berlin). 31:1973;205-214.
7. Casey D.E., Gerlach J., Christenson E. Behavioural aspects of GABA interrelationships in the monkey. Brain Res. Bull. 5(S2):1980;269-273.
8. Chipkin R.E., Iorio L.C., Coffin V.L., McQuade R.D., Berger J.G., Barnet A. Pharmacological profile of SCH39166: a dopamine D-1 selective benzonapthazepine with potential antipsychotic activity. J. Pharmacol. Exp. Ther. 247:1988;1093-1102.
9. Costall B., Hui S.-C.G., Metcalf G., Naylor R.J. A study of the changes in motor behaviour caused by TRH on intracerebral injection. Eur. J. Pharmacol. 53:1979;143-150.
10. Crespi F., Keane P.E., Morre M. In vivo evaluation by differential pulse voltammetry of the effect of thyrotrophin-releasing hormone (TRH) on dopaminergic synaptic activity in the striatum and nucleus accumbens of the rat. Exp. Brain Res. 62:1986;329-334.
11. Dursun S.M., Handley S.L. Tic-like behaviours induced by TRH-amide: differential effects of ritanserin and haloperidol. Br. J. Pharmacol. 102:1991;229P.
12. 2A receptors are active under physiological conditions. Psychopharmacology. 128:1996;198-205.
13. 2 receptors. Psychopharmacology. 106:1992;447-454.
14. 2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J. Pharmacol. Exp. Ther. 259:1991;595-600.
15. Fone K.C.F., Bennett G.W., Marsden C.A. Involvement of catecholaminergic neurones and alpha-adrenoceptors in the forepaw licking behaviour produced by the intrathecal injection of an analogue of thyrotrophin releasing hormone (CG3509). Neuropharmacology. 26:1987;1147-1155.
16. 2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analog (CG3509) to rats. Br. J. Pharmacol. 96:1989;599-608.
17. Fone K.C.F., Johnson J.V., Marsden C.A., Bennett G.W. Comparative behavioural and biochemical effects of repeated intrathecal administration of thyrotrophin-releasing hormone (TRH) or two analogues of TRH in adult rats. Neuropharmacology. 28:1989;867-875.
18. Gilbert R.F.T., Emson P.C., Hunt S.P., Bennett G.W., Marsden C.A., Sandberg B.E.B., Steinbusch H.W.M., Verhofstad A.A.J. The effects of monoamine neurotoxins on peptides in the rat spinal cord. Neuroscience. 7:1982;69-87.
19. Hall A. The origin and purposes of blinking. Br. J. Opthalmol. 29:1945;445-467.
20. Heal D.J., Sabbagh A., Youdim M.B.H., Green A.R. Behavioural effects of central and peripheral injection of various analogues and metabolites of thyrotrophin releasing hormone (TRH). Neuropharmacology. 20:1981;947-957.
21. Helms P.M., Goodwin C.D. Abnormalities of blink rate in psychoses: a preliminary report. Biol. Psych. 20:1985;103-106.
22. Iorio L.C., Barnett A., Ceitz F.H., House V.P., Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226:1983;462-468.
23. Johnson J.V., Fone K.C.F., Havler M.E., Tulloch I.F., Bennett G.W., Marsden C.A. A comparison of the motor behaviours produced by the intrathecal administration of thyrotrophin releasing hormone analogues in the conscious rat. Neuroscience. 29:1989;463-470.
24. Karson C.N., Fred W.J., Kleinman J.E., Bigelow L.B., Wyatt R.J. Neuroleptics decrease blinking in schizophrenic subjects. Biol. Psychiatry. 16:1981;679-682.
25. Karson C.N., Bigelow L.B., Kleinman J.E., Weinberger D.R., Wyatt R.J. Haloperidol-induced changes in blink rates correlate with changes in BPRS-score. Br. J. Psychiatry. 140:1982;503-507.
26. Karson C.N., Kleinman J.E., Berman K.F., Phelps B.H., Wise C.D., De Lise L.E., Jeste D.V. An inverse correlation between spontaneous eye blink rate and platelet monoamine oxidase activity. Br. J. Psychiatry. 142:1983;43-46.
27. Karson C.N. Spontaneous eye blink rates and dopaminergic systems. Brain. 106:1983;643-653.
28. 1C receptors mediate 1-3(chlorophenyl) piperazine-induced hypophagia. Br. J. Pharmacol. 103:1991;2016-2020.
29. 2C/2B receptor antagonist. Br. J. Pharmacol. 111:1994;797-802.
30. 3H ]-dopamine from slices of rat nucleus accumbens in vitro Br. J. Pharmacol. 67:1979;323-325.
31. Kleinman J.E., Karson C.N., Weinberger D.R., Freed W.J., Berman K.F., Wyatt R.J. Eye blinking and cerebral ventricular size in chronic schizophrenic patients. Am. J. Psychiatry. 141:1984;1430-1432.
32. Lawrence M.S., Redmond D.E. Jr. MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys. Pharmacol. Biochem. Behav. 38:1991;869-874.
33. 1 receptor antagonist, SCH 23390, induces signs of Parkinsonism in African green monkeys. Life Sci. 49:1991;229-234.
34. Lighton C., Marsden C.A., Bennett G.W. The effects of 5,7-dihydroxytryptamine and p-chlorophenylalanine on thyrotrophin-releasing hormone in regions of the brain and spinal cord of the rat. Neuropharmacology. 23:1984;55-60.
35. Linthorst A.C.E., Broekhoven M.H., De Jong W., Van Wimersma Greidanus T.B., Versteeg D.H.G. Effects of SCH23390 and quinpirole on novelty-induced grooming behaviour in spontaneously hypertensive rats and Wistar-Kyoto rats. Eur. J. Pharmacol. 219:1992;23-28.
36. Mackert A., Fletchtner K., Woyth C., Frick K. Increased blink rates in schizophrenics: influences of neuroleptics and psychopathology. Schizophr. Res. 4:1991;41-47.
37. McCreary A.C., Handley S.L. TRH analogue MK771 induces blinking; evidence for serotonergic modulation. Br. J. Pharmacol. 107S:1992;450P.
38. McCreary A.C., Handley S.L. TRH analogue MK771 induces forepaw licking; evidence for 5-hydroxytryptaminergic modulation. Br. J. Pharmacol. 108S:1993;262P.
39. 2 receptor antagonists. Br. J. Pharmacol. 112:1994;652P.
40. McCreary A.C., Handley S.L. SB 200646A differentially modulates forepaw-tremor and forepaw licking induced by MK771. J. Psychopharmacol. 9:1995;A24-A94.
41. 2B receptors may modulate blinking induced by the TRH analogue MK771. Br. J. Pharmacol. 116S:1995;219P.
42. Miyamoto M., Nagawa Y. Mesolimbic involvement in the locomotor stimulant action of thyrotrophin-releasing hormone (TRH) in rats. Eur. J. Pharmacol. 44:1977;143-152.
43. Miyamoto M., Narumi S., Nagai Y., Shima T., Nagawa Y. Thyrotrophin releasing hormone: hyperactivity and mesolimbic dopamine system in rats. Jpn. J. Pharmacol. 29:1979;335-347.
44. 1 antagonist SCH23390. Psychopharmacology. 82:1984;409-410.
45. 1 dopamine receptor agonist SK and F38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology. 92:1987;164-168.
46. 1 dopamine receptor agonist R-SK and F 38393. J. Psychopharmacol. 1:1987;177-183.
47. Muesser K.T., Dysken M.W., Sussman S., Lyons J.S., Davis J.M. Development of tolerance to neuroleptic-induced decreases in blink rate. Biol. Psychol. 19:1984;617-621.
48. Navarro J.F., Manzaneque J.M., Martin-Lopez M. Effects of three dopaminergic antagonists (haloperidol, tiapride, zuclopenthixol) on grooming behaviour in male mice. Med. Sci. Res. 24:1997;681-682.
49. Nishikawa Y., Ikegami H., Jikihara H., Koike K., Masumoto N., Kasahara K., Tasaka K., Hirota K., Miyake A., Tanizawa O. Effects of thyrotrophin-releasing hormone and phorbol ester on dopamine release from dispersed rat tuberoinfundibular dopaminergic neurons. Peptides. 14:1993;839-844.
50. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology. 90:1986;287-294.
51. Plotnikoff N.P., Prange A.J. Jr., Breese G.R., Anderson M.S., Wilson I.C. Thyrotrophin releasing hormone: enhancement of DOPA activity by a hypothalamic hormone. Science. 178:1972;417-418.
52. Plotnikoff N.P., Breese G.R., Prange A.J. Jr. Thyrotrophin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies. Pharmacol. Biochem. Behav. 3:1975;665-770.
53. Przegalinski E., Jaworska L. The effect of repeated administration of anti-depressant drugs on the thyrotrophin-releasing hormone (TRH) content of rat brain structures. Psychoneuroendocrinology. 15:1990;147-153.
54. Przegalinski E., Jaworska L., Golembiowska K. The effect of fenfluramine on the thyrotrophin-releasing hormone (TRH) content in the rat brain structures and lumbar spinal cord. Neuropeptides. 15:1990;195-200.
55. Rastogi R.B., Singhal R.L., Lapierre Y.D. Effects of MK-771, a novel TRH analog, on brain dopaminergic and serotonergic systems. Eur. J. Pharmacol. 73:1981;307-312.
56. Sasek C.A., Wessendorf M.W., Helke C.J. Evidence for co-existence of thyrotrophin-releasing hormone, substance P and serotonin in ventral medullary neurons that project to the intermediolateral cell column in the rat. Neuroscience. 35:1990;105-119.
57. Schaeffer, R.L., Farber, E., 1992. Minitab Statistical Manual, Release 8. Addison-Wesley, New York, NY.
58. 1A agonists. J. Pharmacol. Exp. Ther. 273:1995;101-112.
59. Sharif, N.A., 1989. Quantitative autoradiography of TRH receptors in discrete brain regions of different mammalian species. In: Metcalf G., Jackson I.M.D. (Eds.), Thyrotrophin-releasing Hormone, Biomedical Significance. Ann. New York Acad. Sci. 553, 147-174.
60. Sharp T., Bennett G.W., Marsden C.A. Thyrotrophin-releasing hormone analogues increase dopamine release from slices of rat brain. J. Neurochem. 39:1982;1763-1766.
61. Simasko S.M., Horita A. Treatment of rats with the TRH analog MK771: down-regulation of TRH receptors and behavioural tolerance. Neuropharmacology. 24:1985;157-165.
62. 2 antagonists and high doses of SCH23390. Pharmacol. Biochem. Behav. 24:1986;837-839.
63. 2 receptors. Neuropharmacology. 25:1986;455-463.
64. 1 agonist, reduces MPTP-induced Parkinsonism in monkeys. Eur. J. Pharmacol. 199:1991;389-391.
65. Veber, D.F., Holly, F.W., Varga, S.L., Hirschnamm, R., Nutt, R.F., Lotti, V.J., Porter, C.C., 1976, The dissociation of hormonal and CNS effects in analogs of TRH. In: Loffet, A. (Ed.), Proceedings 14th European Peptide Symposium. University of Brussels Press, Belgium.
66. 2 dopaminergic function. Adv. in Med. Biol. 204:1986;125-136.
67. Wei E. Thyrotrophin-releasing hormone and shaking behaviour in rat. Nature. 253:1975;739-740.
68. Wei E.T. Pharmacological aspects of shaking behaviour produced by TRH, AG-3-5, and morphine withdrawal. Fed. Proc. 40:1981;1491-1496.
69. 1 muscarinic receptor antagonist. Neurochem. Int. 16:1990;281-285.
70. Yamada K., Demarest K.T., Moore K.E. Effects of behaviourally active doses of thyrotrophin-releasing hormone and its analog MK771 on dopaminergic neuronal systems in the brain of the rat. Neuropharmacology. 23:1984;735-739.
71. Yarbrough G.G. Studies on the neuropharmacology of thyrotrophin releasing hormone (TRH) and a new TRH analog. Eur. J. Pharmacol. 48:1978;19-27.